Owl Therapeutics
Biotechnology company developing therapeutics that modulate microglia — the brain's immune cells — for neurodegenerative and brain-injury indications. The organization combines generative AI-driven molecule engineering, biomarker-driven translational workflows, and high-throughput functional assays to advance antibody, fusion-protein, and small-molecule candidates from preclinical into clinical development.
Industries
Nr. of Employees
small (1-50)
Owl Therapeutics
Cambridge, Massachusetts, United States, North America
Products
Monoclonal antibody therapeutic candidate (late preclinical)
Biologic candidate engineered to enhance microglial phagocytosis of brain cell debris; in late preclinical development.
Fusion-protein therapeutic candidate (late preclinical)
Fusion-protein candidate engineered to enhance microglial clearance of inflammatory signals; in late preclinical development.
Small-molecule neuroprotective candidate (clinical and early preclinical)
Small-molecule candidate focused on protecting mitochondrial function in microglia and other brain cells; has assets in clinical and early preclinical stages.
Monoclonal antibody therapeutic candidate (late preclinical)
Biologic candidate engineered to enhance microglial phagocytosis of brain cell debris; in late preclinical development.
Fusion-protein therapeutic candidate (late preclinical)
Fusion-protein candidate engineered to enhance microglial clearance of inflammatory signals; in late preclinical development.
Small-molecule neuroprotective candidate (clinical and early preclinical)
Small-molecule candidate focused on protecting mitochondrial function in microglia and other brain cells; has assets in clinical and early preclinical stages.
Services
Biomarker-driven translational collaboration
Collaborative reverse-translation of clinical blood biomarkers into preclinical models to inform candidate selection and development.
Strategic licensing and clinical collaboration services
Execution of licensing and clinical collaboration agreements to enable clinical advancement of therapeutic candidates.
Biomarker-driven translational collaboration
Collaborative reverse-translation of clinical blood biomarkers into preclinical models to inform candidate selection and development.
Strategic licensing and clinical collaboration services
Execution of licensing and clinical collaboration agreements to enable clinical advancement of therapeutic candidates.
Expertise Areas
- Microglia-targeted therapeutics
- Generative AI-driven drug discovery
- Translational biomarker development
- Antibody and fusion-protein engineering
Key Technologies
- Generative AI for molecular design
- High-throughput functional screening
- Blood-based biomarker reverse-translation
- Monoclonal antibody engineering